You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 31, 2025

Claims for Patent: 7,105,489

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,105,489

Title:	Methods and compositions for treating polycystic ovary syndrome
Abstract:	The present invention relates to methods of treating polycystic ovary syndrome (PCOS) comprising administering glucagon-like peptide-1 (GLP-1) to subjects suffering therefrom.
Inventor(s):	Hathaway; David R. (Lincoln, NE)
Assignee:	Amylin Pharmaceuticals, Inc. (San Diego, CA)
Application Number:	10/317,126
Patent Claims:	1. A method of treating a subject suffering from polycystic ovary syndrome (PCOS) comprising the step of administering to a subject suffering from PCOS an amount of a GLP-1 molecule effective to treat at least one symptom of PCOS. 2. The method according to claim 1, wherein the symptom is selected from the group consisting of insulin resistance, hyperinsulinemia, type-2 diabetes, obesity, hypertension, hyperlipidemia, anovulation or irregular ovulation, infertility, hyperandrogenism, hirsutism, alopecia, acne, enlarged multifollicular ovaries; abnormal uterine bleeding, and spontaneous abortion. 3. A method of reducing insulin resistance in a subject suffering from PCOS comprising the step of administering to a subject suffering from PCOS an amount of a GLP-1 molecule effective to reduce insulin resistance, wherein said insulin resistance is a symptom of PCOS. 4. A method of preventing the onset of type-2 diabetes in a subject suffering from PCOS comprising the step of administering to a subject suffering from PCOS an amount of a GLP-1 molecule effective to prevent the onset of type-2 diabetes, wherein said type-2 diabetes is a symptom of PCOS. 5. A method of restoring regular menses in a subject suffering from PCOS comprising the step of administering to a subject suffering from PCOS an amount of a GLP-1 molecule effective to restore regular menses, wherein irregular menses is a symptom of PCOS. 6. A method of restoring regular ovulation in a subject suffering from PCOS comprising the step of administering to a subject suffering from PCOS an amount of a GLP-1 molecule effective to restore regular ovulation, wherein anovulation or irregular ovulation is a symptom of PCOS. 7. A method of restoring fertility in a subject suffering from PCOS comprising the step of administering to a subject suffering from PCOS an amount of a GLP-1 molecule effective to restore fertility, wherein the infertility is a symptom of PCOS. 8. A method for preventing spontaneous abortion in a subject suffering from PCOS comprising the step of administering to a subject suffering from PCOS an amount of a GLP-1 molecule effective to prevent spontaneous abortion, wherein said spontaneous abortion is a symptom of PCOS. 9. The method according to any one of claims 1 to 8, wherein the subject is human. 10. The method according to any one of claims 1 to 8, wherein the GLP-1 molecule is selected from the group consisting of GLP-1(7 36)NH.sub.2, GLP-1(7 37), and exendin-4. 11. The method according to any one of claims 1 to 8, wherein the GLP-1 molecule is selected from the group consisting of GLP-1(7 36)NH.sub.2 and GLP-1(9 36)NH.sub.2. 12. The method according to any one of claims 1 to 8 wherein the GLP-1 is coadministered by an infusion pump or by subcutaneous injection of a slow release formulation. 13. The method according to any one of claims 1 to 8 wherein the GLP-1 is coadministered with an agent selected from the group consisting of an ovulation inducing drug, an anti-androgenic drug, an insulin-sensitizing agent and glucose. 14. The method according to claim 13 wherein the ovulation inducing drug is selected from the group consisting of clomiphene, follistim, and Gonal-F. 15. The method according to claim 13 wherein the anti-androgenic drug is selected from the group consisting of a birth control pill, spironolactone, flutamide, and finasteride. 16. The method according to claim 13 wherein the insulin-sensitizing agent is selected from the group consisting of metformin, D-Chiro-inositol, diazoxide, and PPAR inhibitor. 17. The method according to claim 13, wherein the glucose is administered intravenously. 18. The method according to claim 13, wherein the GLP-1 and the agent are administered either sequentially or concurrently. 19. The method of claim 16, wherein said PPAR inhibitor is triglitazone, rosiglitazone, or pioglitazone. 20. The method according to any one of claims 1 to 8, wherein the GLP-1 molecule is exendin-4.

Details for Patent 7,105,489

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emd Serono, Inc.	GONAL-F	follitropin alfa	For Injection	020378	September 29, 1997	⤷ Get Started Free	2022-12-11
Emd Serono, Inc.	GONAL-F	follitropin alfa	For Injection	020378	March 25, 2004	⤷ Get Started Free	2022-12-11
Emd Serono, Inc.	GONAL-F	follitropin alfa	For Injection	020378	February 28, 2001	⤷ Get Started Free	2022-12-11
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.